Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Amortization of Deferred Charges (2022 - 2023)

Century Therapeutics (IPSC) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $38000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Amortization of Deferred Charges fell 50.0% to $38000.0 in Q2 2023 year-over-year; TTM through Dec 2023 was $94000.0, a 68.56% decrease, with the full-year FY2023 number at $94000.0, down 68.56% from a year prior.
  • Amortization of Deferred Charges was $38000.0 for Q2 2023 at Century Therapeutics, down from $56000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $78000.0 in Q3 2022 to a low of $38000.0 in Q2 2023.